MOS is dedicated to ensuring you stay informed during the COVID-19 crisis. Click above to find all of the latest resources from ASCO, ASH, COA, HOSS, and important Industry News related to the crisis.
BREAKING NEWS: National healthcare organizations urge Governors and Insurance Commissioners throughout the country to support broad coverage and payment of telemedicine services even after the COVID-19 pandemic ends. Read the letters to the Governors and the Insurance Commissioners here.
The Mississippi Society of Oncology was formed in 1991 for the purpose ofpromoting the highest professional standards of oncology in Mississippi, to study, research and exchange information, experiences and ideas leading to improvement in oncology and promote educational opportunities.
In addition, the MOS is committed to support the search for more effective treatments of malignant diseases, work with other organizations and societies that have concerns with cancer care, and disseminate information regarding regulatory developments affecting members.
And finally the MOS acts as a resource for insurers regarding the standard of care in oncology and represents the practice of oncology and hematology in the State of Mississippi.
MOS is happy to have partnered with NCODA to present their most recent webinars. You can watch all five parts of the COVID-19 series and a special ASCO/NCODA webinar on Patient-Centered Standards for Medically Integrated Dispensing by clicking HERE.
CORONAVIRUS INFORMATION FROM THE CDC
CDC is working across the Department of Health and Human Services and across the U.S. government in the public health response to COVID-19.
Please see links below for additional information:
IMPORTANT INFORMATION FOR ALL PROVIDERS FROM THE AMERICAN MEDICAL ASSOCIATION
As of January 1, 2021, there will be significant changes to the office and outpatient Evaluation and Management (E&M) services (CPT ® codes 99202-99215) for both new and established patients. Find out more
Most Favored Nation Interim Final Rule Will Devastate Cancer Care
The American Society of Clinical Oncology (ASCO) filed an amicus curiae brief in support of motions in three cases to stop the Most Favored Nation (MFN) model from taking effect on January 1, 2021. ASCO’s brief urges the court to stop implementation of the model, citing its devastating impact on patients. CMS projects that the model will cause 19% of beneficiaries to lose access to its 50 targeted drugs, 38 of which are used in cancer treatment. In addition, ASCO estimates that independent community oncology practices will see a 52% average loss of Medicare drug revenue once the model is fully phased in and that hospital outpatient oncology departments will see an average loss of 50% by year four of the model. Read the Society’s full amicus curiae brief and comments submitted to CMS about the MFN Model.
January 7, 2011 - Congress recently passed an end-of-year legislative package that provides federal funding for Fiscal Year (FY) 2021 and includes numerous provisions that will directly impact patients with cancer and their entire cancer care team. Find out more
December 10, 2020 - Community Oncology Alliance Applauds Supreme Court Ruling Supporting State Regulations of PBMs, Find out more
October 13, 2020 - The Latest Circuit Court Ruling on 340B Program Effect on Practices, Find out more
October 8, 2020 - On October 2, after consultation with public health officials, Department of Health and Human Services (HHS) Secretary Alex Azar, pursuant to the authority vested in him under section 319 of the Public Health Service Act, renewed the public health emergency effective October 23, 2020.
October 6, 2020 - Supreme Court scrutinizes Arkansas law that regulates PBM payments to pharmacies, Find out more
RxVantage recently shared a panel discussion of oncology experts from around the country who have exhibited impressive leadership amid COVID-19. These executives met via video conference to share experiences, discuss strategies that have worked (as well as those that have not), and their plans for moving forward. Click below to view each presentation:
On October 21, 2020, the Centers for Medicare & Medicaid Services (CMS) announced plans to delay the start date of the Radiation Oncology (RO) model until July 1, 2021. The change comes following stakeholder concerns—the Association for Clinical Oncology (ASCO) among them—about the challenges of implementing the model by the initial start date, January 1, 2021, during the COVID-19 pandemic.
The American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as, how COVID-19 is impacting the delivery of cancer care and patient outcomes. ASCO will deliver periodic reports with key findings so that the oncology community has real-time information to help inform treatment approaches for patients with cancer who have a confirmed COVID-19 infection. The reports will allow practices to easily and confidentially share information on COVID-19 infections among their patients.
NEW ASH Virtual Listening Sessions on Diversity, Equity, and Inclusion
Coming soon: The ASH Virtual Listening Sessions on Diversity, Equity, and Inclusion will explore issues facing those from backgrounds traditionally disadvantaged in medicine, as well as DEI opportunities in the hematology community. ASH is currently seeking participants willing to share their thoughts and experiences on DEI issues related to race, ethnicity, gender, ability, and/or sexual orientation for the first set of listening sessions. ASH members interested in participating in the listening sessions are encouraged to sign up soon as we anticipate significant interest.